https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-14 / J Transl Med 2007 Mar;5:16
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-14 / J Transl Med 2007 Mar;5:162007-03-14 00:00:002007-03-14 00:00:00Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-01 / Oncol. Rep. 2007 Mar;17(3):653-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-01 / Oncol. Rep. 2007 Mar;17(3):653-92007-03-01 00:00:002019-02-15 08:35:07Hyperthermia-enhanced tumor accumulation and antitumor efficacy of a doxorubicin-conjugate with a novel macromolecular carrier system in mice with non-small cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-01 / Expert Rev Anticancer Ther 2007 Mar;7(3):275-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-01 / Expert Rev Anticancer Ther 2007 Mar;7(3):275-832007-03-01 00:00:002019-02-15 08:37:33Dendritic cell vaccines for leukemia patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-01 / J Dtsch Dermatol Ges 2007 Mar;5(3):190-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-01 / J Dtsch Dermatol Ges 2007 Mar;5(3):190-62007-03-01 00:00:002019-02-15 09:19:43Dendritic cell-based immunotherapy of malignant melanoma: success and limitations
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-01 / Eur. Urol. 2007 Mar;51(3):853-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-01 / Eur. Urol. 2007 Mar;51(3):853-42007-03-01 00:00:002019-02-15 09:24:09Re: Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase 1 clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-01 / Curr Cancer Drug Targets 2007 Mar;7(2):157-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-01 / Curr Cancer Drug Targets 2007 Mar;7(2):157-672007-03-01 00:00:002019-02-15 09:22:10Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-01 / Curr Cancer Drug Targets 2007 Mar;7(2):123-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-01 / Curr Cancer Drug Targets 2007 Mar;7(2):123-52007-03-01 00:00:002019-02-15 09:22:11Oncolytic virus therapy–foreword
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-01 / J Natl Compr Canc Netw 2007 Mar;5(3):345-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-01 / J Natl Compr Canc Netw 2007 Mar;5(3):345-82007-03-01 00:00:002007-03-01 00:00:00Counterpoint: Hyperthermia with radiation therapy for chest wall recurrences
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-01 / J Natl Compr Canc Netw 2007 Mar;5(3):339-44
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-01 / J Natl Compr Canc Netw 2007 Mar;5(3):339-442007-03-01 00:00:002007-03-01 00:00:00Point: Hyperthermia with radiation for chest wall recurrences
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-02-27 / Biomed. Pharmacother. 2007 Jul;61(6):306-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-02-27 / Biomed. Pharmacother. 2007 Jul;61(6):306-142007-02-27 00:00:002019-02-15 08:32:36Dendritic cell-based immunotherapy in acute and chronic myeloid leukaemia
